Posted by Michael Wonder on 21 Dec 2016
UCB’s anti-epileptic drug Vimpat (lacosamide) approved as monotherapy by European Commission
20 December 2016 - European monotherapy indication broadens clinical application of Vimpat for people with epilepsy living with partial-onset seizures.
The European Commission has approved a license extension for UCB’s anti-epilepsy drug Vimpat (lacosamide) for use as monotherapy in the treatment of partial-onset seizures (POS) in adult and adolescent (16-18 years) patients with epilepsy.
The approval comes into immediate effect, following a positive opinion recommendation from the CHMO in November 2016.
